R&D channel feed

Bio­gen to halt sales and de­vel­op­ment of con­tro­ver­sial Alzheimer's drug Aduhelm

Last year
Pharma

Up­dat­ed: No­var­tis ax­es blood can­cer drug af­ter PhI­II flop, cau­tions on obe­si­ty FO­MO

Last year
Pharma

Gilead in­vests an­oth­er $320M in Ar­cus as part­ners re­hash their TIG­IT pact

Last year
Deals
Pharma

Ex­clu­sive: Jnana says piv­otal tri­al of PKU pill could be­gin next year af­ter promis­ing re­sults from a small­er study

Last year

Ver­tex’s pain drug suc­ceeds in late-stage stud­ies, mark­ing ma­jor break­through in search for new, non-opi­oid med­i­cines

Last year

FDA sched­ules March ODAC for Geron's MDS drug fol­low­ing PhI­II da­ta

Last year
FDA+

Sarep­ta shares PhII da­ta for next-gen ex­on skip­ping drug, but reg­u­la­to­ry path­way is un­clear

Last year

Roche ends KRAS deal with Hookipa Phar­ma, as biotech lays off 30% of staff

Last year
People
Deals

Bris­tol My­er­s' Op­di­vo fails part two of post-kid­ney can­cer surgery test as com­peti­tor Mer­ck touts new sur­vival da­ta

Last year
Pharma

First-ever RNA edit­ing tri­al in US gets clear­ance, pit­ting ‘ex­on edit­ing’ tech­nol­o­gy against vi­sion loss

Last year

Bio­phar­ma in­dus­try's vac­cine pipeline lacks ‘depth,' with an overem­pha­sis on Covid — re­port

Last year
Coronavirus

Mer­ck de­tails win for Keytru­da in blad­der can­cer af­ter surgery

Last year

Ex­clu­sive: Strand lays off 18% of staff as its first mR­NA ther­a­pies head in­to the clin­ic

Last year
People

Shang­hai star­tup's gene ther­a­py re­stores hear­ing in five deaf chil­dren, run­ning ahead of Lil­ly and Re­gen­eron tri­als

Last year
Cell/Gene Tx

Roche and Ex­elix­is de­tail rare suc­cess for Cabome­tyx-Tecen­triq com­bo in prostate can­cer

Last year
Pharma

Eli Lil­ly says its po­ten­tial gene ther­a­py 're­stored hear­ing' in 11-year-old boy

Last year
Cell/Gene Tx

Sanofi wades in­to AATD in $1.7B bid for In­hi­brx's rare dis­ease drug

Last year
Deals

Io­n­is touts PhI­II suc­cess for rare dis­ease drug amid com­pa­ny's push to com­mer­cial­ize drugs in­de­pen­dent­ly

Last year

Lack­lus­ter da­ta on Alzheimer's drugs lead to end of Roche-AC Im­mune part­ner­ship

Last year
Deals
Pharma

Trodelvy fails PhI­II lung can­cer study in blow to Gilead’s ADC ex­pan­sion plans

Last year

Hi­ber­na­tion re­search could lead to new weight loss med­i­cines — could it al­so help as­tro­nauts in space?

Last year
Deals

As­traZeneca's Imfinzi com­bo ex­tends PFS in liv­er can­cer; No­var­tis shares new de­tails about Lu­tather­a's PhI­II

Last year

Af­ter Bris­tol My­ers pulls out of col­lab­o­ra­tion, Ike­na On­col­o­gy lays off 35% of staff and trims can­cer pipeline

Last year
People

CAR NK ther­a­py looks durable in a small tri­al, giv­ing in­sight in­to large Take­da study

Last year
Cell/Gene Tx
First page Previous page 56575859606162 Next page Last page
A service from the Financial Times